BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20152220)

  • 1. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Levy PD; Nandyal D; Welch RD; Sun JL; Pieper K; Ghali JK; Fonarow GC; Gheorghiade M; O'Connor CM
    Am Heart J; 2010 Feb; 159(2):222-230.e2. PubMed ID: 20152220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors.
    Setoguchi S; Levin R; Winkelmayer WC
    Int J Cardiol; 2008 Apr; 125(2):172-7. PubMed ID: 17997175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
    Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Card Fail; 2007 Nov; 13(9):722-31. PubMed ID: 17996820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
    Brackbill ML; Bashaw-Keaton R; Sytsma CS
    Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
    Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
    Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF).
    Fonarow GC; Abraham WT; Albert NM; Gattis Stough W; Gheorghiade M; Greenberg BH; O'Connor CM; Pieper K; Sun JL; Yancy CW; Young JB;
    Arch Intern Med; 2007 Jul; 167(14):1493-502. PubMed ID: 17646603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure: is there a role for angiotensin II receptor blockers?
    Boucher M; Ma J
    Issues Emerg Health Technol; 2002 Sep; (38):1-4. PubMed ID: 12243202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
    McAlister FA; Ghali WA; Gong Y; Fang J; Armstrong PW; Tu JV
    Circulation; 2006 Jun; 113(22):2572-8. PubMed ID: 16735672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge.
    Butler J; Arbogast PG; Daugherty J; Jain MK; Ray WA; Griffin MR
    J Am Coll Cardiol; 2004 Jun; 43(11):2036-43. PubMed ID: 15172409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin.
    Guazzi M; Brambilla R; Reina G; Tumminello G; Guazzi MD
    Arch Intern Med; 2003 Jul; 163(13):1574-9. PubMed ID: 12860580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underutilization of angiotensin converting enzyme inhibitors among heart failure patients.
    Lean QY; Shamsuddin N; Wan Ahmad WA
    Med J Malaysia; 2008 Aug; 63(3):216-21. PubMed ID: 19248693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
    Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
    Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J
    Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.